Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Radiotherapy blasts forward

Who's doing what in next-generation targeted radiotherapies for cancer

January 25, 2020 4:46 AM UTC
Updated on Feb 5, 2020 at 10:15 PM UTC

High-wattage takeouts and commercial launches have revived interest in radiopharmaceuticals for cancer. The challenge for the new wave of candidates is to achieve enough differentiation to justify the logistical hurdles of manufacturing and delivering products that rapidly decay.

The excess nuclear energy released by radioisotopes as they decay to a more stable state can be harnessed to detect in vivo signals, or to kill pathogenic cells by inducing DNA damage...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article